Immune checkpoint inhibitors (ICIs) enhance the cytotoxicity effect of T cells on tumor cells by acting on co-inhibitory receptors such as CTLA-4 and PD-1 or their ligands such as programmed death ligand-1 (PD-L1) [50]. Here, CTLA4 is linked to neoplasm.